---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014700"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T12:31:58.611973+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma appoints new director, amends equity facility to raise up to $20M

## Summary
- Andrew Ritter resigned from board effective June 9, 2025.
- David C. Mun-Gavin appointed as director and chair of compensation committee on June 10, 2025.
- Amendment to Common Shares Purchase Agreement increases Bristol Capital's beneficial ownership limit to 9.99%.
- Equity facility remains at $20M; change gives more flexibility for future stock sales.

## SEC filing metadata
- accession: 0001641172-25-014700
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/0001641172-25-014700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014700
- JSON: https://secwatch.observer/filing/0001641172-25-014700.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014700.txt

## Key facts
- Executive change
  David C. Mun-Gavin was appointed as Non-employee Director and Chair of the Compensation Committee at GT Biopharma, Inc..
  - Action: appointed
  - Role: Non-employee Director and Chair of the Compensation Committee
  source text: On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/0001641172-25-014700-index.htm
- Executive change
  Andrew Ritter resigned as Member of the Board of Directors at GT Biopharma, Inc..
  - Action: resigned
  - Role: Member of the Board of Directors
  source text: On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000164117225014700/0001641172-25-014700-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.